Risk of severe allergic reactions to COVID‐19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts
Johannes Ring, Margitta Worm, Andreas Wollenberg, Jacob P. Thyssen, Thilo Jakob, Ludger Klimek, Christine Bangert, S. Barbarot, Thomas Bieber, Marjolein de Bruin‐Weller, Pavel V. Chernyshov, Stéphanie Christen‐Zaech, Michael J. Cork, Ulf Darsow, Carsten Flohr, Regina Fölster‐Holst, C. Gelmetti, Uwe Gieler, Jan Gutermuth, Annice Heratizadeh, DirkJan Hijnen, L.B. von Kobyletzki, B Kunz, C. Paul, L. De Raeve, Julien Sénéschal, Dagmar Simon, Phyllis I. Spuls, J.F. Stalder, Åke Svensson, Zsuzsanna Szalai, Alain Taı̈eb, Antonio Torrelo, Magdalena Trzeciak, Christian Vestergaard, Thomas Werfel, Stephan Weidinger, Mette Deleuran
Abstract
Since the introduction of active vaccination against SARS‐CoV‐2 infection, there has been a debate about the risk of developing severe allergic or anaphylactic reactions among individuals with a history of allergy. Indeed, rare cases of severe allergic reactions have been reported in the United Kingdom and North America. By February 2021 a rate of 4,5 severe allergic reactions occurred among 1 million patients vaccinated with the mRNA‐based COVID‐19 vaccines, which is higher than the generally expected rate of severe allergic reactions to vaccinations of around 1 in 1 million.